Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,405 across all filing types
Latest filing 2018-07-24 Regulatory Filings
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ATACAND TO BE DIVESTED TO CHEPLAPHARM IN EUROPE
Regulatory Filings
2018-07-24 English
Atacand to be divested to Cheplapharm in Europe
Regulatory Filings Classification · 98% confidence The document begins with an 'RNS Number' and is dated July 24, 2018. The content describes a definitive agreement for AstraZeneca to sell commercial rights for a drug (Atacand) to Cheplapharm, including financial considerations ($200 million upfront payment). This is a corporate transaction announcement related to asset divestiture, which falls under the scope of major corporate activities. Since it is explicitly marked as an RNS release and details a significant transaction (divestiture/sale of rights), it is best classified as a general Regulatory Filing (RNS) or potentially a Merger/Acquisition Activity (TAR). Given the context of selling off a mature product line, it is a significant corporate event announcement. However, the presence of the RNS header and the nature of the announcement (a definitive agreement for asset sale) strongly suggests a general regulatory disclosure. Since TAR is specifically for M&A proposals/takeover bids, and this is an asset sale, RNS is the most appropriate general regulatory disclosure category, especially since the document ends by referencing RNS as the source.
2018-07-24 English
Holding(s) in Company
Major Shareholding Notification Classification · 99% confidence The document is explicitly identified by the 'RNS Number' header and contains the phrase 'This information is provided by RNS, the news service of the London Stock Exchange.' RNS stands for Regulatory News Service. The content itself is a 'TR-1: Standard form for notification of major holdings,' which is a mandatory regulatory filing concerning changes in significant share ownership (AstraZeneca PLC crossing the 15% threshold to 19.9%). This type of filing, reporting changes in major shareholdings, fits best under the 'Major Shareholding Notification' category (MRQ). Although it is a regulatory filing (RNS), MRQ is the more specific classification for this content type.
2018-07-18 English
HOLDING(S) IN COMPANY
Regulatory Filings
2018-07-18 English
Regulatory Filings 2018
Regulatory Filings
2018-07-03 English
TOTAL VOTING RIGHTS
Regulatory Filings
2018-07-02 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.